Skip to content
OpenCapital
Get started

Stoke Therapeutics, Inc. STOK Cash ratio

Cash ratio at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.2×-0.8×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
0.3×-1.2×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
13.7×+10.1×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
10.7×+6.5×
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
2.7×-0.1×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
0.8×-0.1×

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$1.94B+436%
Enterprise value$1.79B+1,855%
P/S60.4×+58.5×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0×0.0×
Current ratio9×+0.6×

Where this comes from

Calculated from Stoke Therapeutics, Inc.’s reported figures.

cash and equivalents/total current liabilities=3.8×

Based on the most recent quarter.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s cash ratio?
Stoke Therapeutics, Inc. (STOK) reported cash ratio of 3.8× in Q1 2026.
How has Stoke Therapeutics, Inc.'s cash ratio changed year-over-year?
Stoke Therapeutics, Inc.'s cash ratio decreased by 38.0% year-over-year, from 6.2× to 3.8×.
What is the long-term trend for Stoke Therapeutics, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s cash ratio has grown at a -43.4% compound annual growth rate (CAGR), from 25.1× to 1.5×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.